Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo A D, Lickrish G, Colgan T, Chapman W, Shaw P
Department of Obstetrics and Gynecology, University of Toronto, Toronto-Synnybrook Regional Cancer Centre, Ontario, M4N 3M5, Canada.
Gynecol Oncol. 2002 Jan;84(1):145-9. doi: 10.1006/gyno.2001.6493.
The aims of this study were (1) to determine the incidence and factors predictive for pathologic parametrial involvement in clinical stage IA1/2 and IB1 cervical cancer after radical surgery and (2) to identify a population at low risk for pathologic parametrial involvement.
All patient information was collected prospectively and extracted from a cervical cancer radical surgery database. Selection criteria for surgery were generally based upon tumor size, with the cutoff for surgery between 3 and 4 cm. Parametrial involvement (PI) was defined as either positive parametrial lymph nodes (PMLN) or malignant cells in the parametrial tissue (PT) (including lymphovascular channels) by either contiguous or discontiguous spread. Statistical analysis included the chi2 test, the Wilcoxon rank test, and the Mantel-Haentzel test.
Between July 1984 and January 2000, 842 patients underwent radical surgery for clinical stage IA1/2 and IB1 cervical cancer at our center. Forty-nine patients (6%) had positive pelvic lymph nodes. Thirty-three patients (4%) had pathologic PI, 8 in the PMLN and 25 in the PT (none had both). PI was associated with older age (42 vs 40 years, P < 0.04), larger tumor size (2.2 vs 1.8 cm, P < 0.04), higher incidence of capillary-lymphatic space invasion (85% vs 45%, P = 0.0004), tumor grades 2 and 3 (95% vs 65%, P = 0.001), greater depth of invasion (18.0 vs 5.0 mm, P < 0.001), and pelvic lymph node metastases (44% vs 5%, P < 0.0001). The incidence of PI in patients with tumor size < or =2 cm, negative pelvic lymph nodes, and depth of invasion < or =10 mm was 0.6%.
Pathologic parametrial involvement in clinical stage IA1/2 and /IB1 cervical cancer is uncommon. Acknowledging that almost all patients with pelvic lymph node metastases and a high proportion of patients with tumor invasion >10 mm will receive adjuvant radiation regardless of the radicality of surgery, a population at low risk for pathologic parametrial involvement can be identified. These patients are worthy of consideration for studies of less radical surgery performed in conjunction with pelvic lymphadenectomy.
本研究的目的是:(1)确定根治性手术后临床分期为IA1/2和IB1期宫颈癌患者的病理宫旁组织受累的发生率及预测因素;(2)识别病理宫旁组织受累低风险人群。
前瞻性收集所有患者信息,并从宫颈癌根治手术数据库中提取。手术选择标准一般基于肿瘤大小,手术临界值为3至4厘米。宫旁组织受累(PI)定义为宫旁淋巴结阳性(PMLN)或宫旁组织(PT)(包括淋巴管)中存在恶性细胞(连续或不连续扩散)。统计分析包括卡方检验、威尔科克森秩和检验以及曼特尔-亨泽尔检验。
1984年7月至2000年1月,本中心842例临床分期为IA1/2和IB1期宫颈癌患者接受了根治性手术。49例患者(6%)盆腔淋巴结阳性。33例患者(4%)有病理PI,8例为宫旁淋巴结阳性,25例为宫旁组织阳性(无两者皆有的情况)。PI与年龄较大(42岁对40岁,P<0.04)、肿瘤较大(2.2厘米对1.8厘米,P<0.04)、毛细血管-淋巴管间隙侵犯发生率较高(85%对45%,P=0.0004)、肿瘤2级和3级(95%对65%,P=0.001)、浸润深度较大(18.0毫米对5.0毫米,P<0.001)以及盆腔淋巴结转移(44%对5%,P<0.0001)相关。肿瘤大小≤2厘米、盆腔淋巴结阴性且浸润深度≤10毫米的患者PI发生率为0.6%。
临床分期为IA1/2和IB1期宫颈癌的病理宫旁组织受累并不常见。鉴于几乎所有盆腔淋巴结转移患者以及高比例肿瘤浸润>10毫米的患者无论手术的根治程度如何都将接受辅助放疗,可识别出病理宫旁组织受累低风险人群。这些患者值得考虑用于联合盆腔淋巴结清扫术的次根治性手术研究。